sur ABIVAX (EPA:ABVX)
Abivax is increasing its participation in investor conferences this autumn
Abivax, a biotechnology company specializing in therapies for chronic inflammatory diseases, has announced its participation in several investor conferences this fall. These events aim to present the progress of its research, particularly its lead drug candidate, obefazimod, currently in Phase 3 trials for the treatment of ulcerative colitis.
Conferences include the Guggenheim Healthcare Innovation Conference in Boston from November 9-11, the LifeSci Capital X Sofinnova Summit in London on November 16, and the German Equity Forum in Frankfurt from November 23-25. Abivax will also speak at the Evercore ISI Healthcare Conference in Miami and the Piper Sandler Healthcare Conference in New York in early December.
The presentations can be followed online via the "Investors" section of the Abivax website.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX